- GSK's R&D overhaul is delivering results with promising treatments for RSV, hepatitis B and asthma.
- Scientists now terminate research projects earlier if they are failing to minimize delays.
- R&D focus is now on infectious disease and HIV, de-emphasizing oncology.
- 70% of the drugs in the company's development pipeline are genetically validated.
- GSK hopes its RSV vaccine could be its next blockbuster.
How GSK plans to replenish its depleted medicine cabinet
GSK's chief scientist says an overhaul of the drugmaker's R&D unit has begun delivering results and pledged a tighter focus than his predecessor on infectious disease and HIV.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ZSS7I2PQORLXXJGNQHTNNYAOBY.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/UQPIK3T2DVOX7EIO4QZCM5HIAA.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ZJM34EMBWJO7BKLC32OVFVZECQ.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/75ZPE5KGUZKI7JLZHA3YCDVDVA.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/VAKMASTY6JJC5EBSX4MM5OEQKM.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/RCWZE2OK3BNCJNRVFOS74NYF7M.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/6W5WJY7T4NLKVFJO5JX37LPYS4.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/BYL7ESQPMFMSNNVJSVCYKYTPH4.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/OGBROYPEZVMVNLCKMBDIE2XJCE.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/JG3AL7UAGVPBJHJUNQS4YZL4SE.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ZSS7I2PQORLXXJGNQHTNNYAOBY.jpg&description=How%20GSK%20plans%20to%20replenish%20its%20depleted%20medicine%20cabinet){kind=link}